Esophageal cancer treated by endoscopic submucosal dissection after neoadjuvant chemoradiotherapy: a case report
© Lim et al.; licensee BioMed Central. 2014
Received: 10 October 2014
Accepted: 26 October 2014
Published: 18 December 2014
The treatment of esophageal cancer remains clinically challenging because of the overall poor prognosis associated with the disease. The mortality rate associated with surgical treatment is high, and the majority of diagnosed patients are old. As such, surgery is not possible in many cases, even when the cancer has progressed to a resectable state.
We present the case of an 82-year-old Korean man who presented to our institution with intermittent odynophagia. Esophageal cancer with submucosal invasion and metastasis to three regional lymph nodes was diagnosed. After neoadjuvant chemoradiotherapy, his regional lymph nodes disappeared. Because of his poor pulmonary function, surgical treatment could not be performed. Endoscopic submucosal dissection was carried out instead, and endoscopic triamcinolone injections were performed serially. Neither recurrence nor abnormal symptoms such as dysphagia or regurgitation have developed for 36 months.
The literature suggests that endoscopic submucosal dissection after chemoradiotherapy is a viable treatment modality in patients with esophageal cancer with a high surgical treatment risk.
KeywordsEndoscopic submucosal dissection Esophageal cancer Neoadjuvant chemoradiotherapy
Esophageal cancer is a highly lethal malignancy with a 5-year survival rate of approximately 15% . Thus, the management of patients with esophageal cancer is challenging and requires a multimodal approach. Suboptimal results have been reported for post-operative adjuvant chemotherapy , radiotherapy  and concurrent chemoradiotherapy ; thus, interest in neoadjuvant treatment has recently increased. In particular, Sjoquist et al. reported that, among patients with resectable esophageal cancer, those who received neoadjuvant chemoradiotherapy showed a significant survival benefit compared to patients who received surgical treatment alone . However, the incidence of esophageal cancer and squamous cell carcinoma is known to increase with age. The incidence of cancer peaks in the seventh decade of human life . Thus, even if resection is possible, surgical treatment cannot be performed in some patients because of their general condition or accompanying comorbidities at the time of diagnosis. In this report, we describe the case of a patient with esophageal cancer who could not undergo surgical treatment because he also had chronic obstructive pulmonary disease (COPD). We successfully treated the patient with endoscopic submucosal dissection (ESD) after concurrent chemoradiotherapy. Our description of the case is accompanied by a discussion of relevant literature.
The patient has been followed on an outpatient basis and has not displayed abnormal symptoms such as dysphagia or regurgitation. Currently, neither local nor distant recurrences of esophageal cancer have been observed after 36 months.
The study protocol was approved by Daegu Fatima Hospital Ethics Committee. The patient gave us written informed consent before the procedure.
As is the case with the majority of gastrointestinal tract malignancies, esophageal cancer has a potentially curative therapy consisting of surgical treatment (esophagectomy with therapeutic lymphadenectomy). However, with recent reports of survival benefits  and complete resection rate increases in patients receiving neoadjuvant chemoradiotherapy , that approach has received attention as a standard treatment for locally advanced esophageal cancer . Our patient had stage IIIA disease at the time of initial diagnosis, but restaging after neoadjuvant chemoradiotherapy showed a significant down-staging effect to stage IA disease.
It is well known that the surgical risk of esophagectomy varies by clinical characteristics such as age and comorbidities. Finlayson et al. reported that the 30-day mortality of esophagectomy was 10.7% among patients in their 60s, but that it increased to 20% among patients in their 80s . Moreover, it is well known that the presence and severity of comorbidities affect disease prognosis as well as surgical outcome. Our patient was 82 years old and exhibited poor pulmonary function. Therefore, we could not perform surgical treatment, despite the fact that his esophageal cancer remained in a resectable state, and we performed ESD instead.
In actuality, endoscopic resection should be avoided in patients with esophageal cancer with submucosal invasion, because there is a substantial risk of regional lymph node metastasis. Ancona et al. reported confirmation of lymph node metastasis in approximately 28% of esophageal cancers with submucosal layer invasion . In our patient, EUS performed during diagnosis showed invasion of the submucosal layer and three regional metastatic nodes. However, EUS performed after neoadjuvant chemoradiotherapy showed an absence of these regional lymph nodes, and ESD was planned only then. Clearly, ESD would not have been planned as a follow-up treatment if, in the initial diagnosis, there were EUS or CT findings that the lesion had invaded the muscularis propria or adventitia or any adjacent structures. Furthermore, we could not directly confirm T stage improvement by EUS prior to ESD, because radiation-induced inflammation of the esophageal wall and residual disease cannot be differentiated easily on EUS scans after neoadjuvant chemoradiotherapy . However, at the time of initial diagnosis, EUS showed only submucosal invasion of the lesion. In addition, as regional lymph nodes showed improvement following neoadjuvant chemoradiotherapy, we indirectly predicted that the T staging of the lesion would not progress beyond T1b. We therefore thoroughly explained the process to the patient and his guardians and acquired informed consent to proceed with ESD.
After neoadjuvant chemoradiotherapy, the lesion area decreased significantly. However, as we performed ESD with a sufficient lateral safety margin, an iatrogenic ulcer that occupied the majority of the short axis of the esophageal lumen unavoidably developed post-operatively. We therefore performed ETI to prevent a secondary luminal stricture. The ETI was performed following a protocol described by Hashimoto et al. . In accordance with that protocol, triamcinolone acetonide (10mg/ml) was placed in a 1-ml syringe. Then, a 25-gauge, 4mm needle (FINEMEDIX, Daegu, South Korea) was used to inject the triamcinolone in increments of 0.2ml (2mg) at 1cm intervals along the long axis and short axis of the ulcer base . No luminal stricture was observed in a follow-up endoscopic examination performed after triamcinolone injection.
The patient remained in a disease-free state without local or distant recurrence 36 months after ESD. This is considered to be due to the fact that the cancer differentiation was not “poor” and the regional lymph node metastases resolved as a result of neoadjuvant chemoradiotherapy. The primary cancer site was also successfully treated to R0 resection through ESD and now shows a good prognosis.
On the basis of our experience in this case, we think that ESD treatment can be considered in patients with resectable esophageal cancer if surgery poses a high risk because of comorbidities or the age of the patient and if there is a good response to neoadjuvant chemoradiotherapy. Furthermore, with respect to the large iatrogenic ulcer that occurred after ESD in our patient, we found that triamcinolone injection via endoscopy was effective in preventing luminal stricture.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Man Hoon Han, MD, for his thoughtful insight into the pathology of esophageal cancer.
- Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009, 27: 5062-5067. 10.1200/JCO.2009.22.2083.View ArticlePubMedGoogle Scholar
- Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H, Japan Clinical Oncology Group: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003, 21: 4592-4596. 10.1200/JCO.2003.12.095.View ArticlePubMedGoogle Scholar
- Zieren HU, Müller JM, Jacobi CA, Pichlmaier H, Müller RP, Staar S: Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 1995, 19: 444-449. 10.1007/BF00299187.View ArticlePubMedGoogle Scholar
- Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007, 8: 545-553. 10.1016/S1470-2045(07)70172-9.View ArticlePubMedGoogle Scholar
- Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011, 12: 681-692. 10.1016/S1470-2045(11)70142-5.View ArticlePubMedGoogle Scholar
- Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol. 2013, 19: 5598-5606. 10.3748/wjg.v19.i34.5598.View ArticlePubMedPubMed CentralGoogle Scholar
- Edge S, Byrd DR, Compton CC, Fritz AG, Greene GL, Trotti A: AJCC Cancer Staging Manual. 2010, New York: Springer, 7Google Scholar
- Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007, 8: 226-234. 10.1016/S1470-2045(07)70039-6.View ArticlePubMedGoogle Scholar
- Courrech Staal EFW, Aleman BMP, Boot H, van Velthuysen MLF, van Tinteren H, van Sandick JW: Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010, 97: 1482-1496. 10.1002/bjs.7175.View ArticlePubMedGoogle Scholar
- Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005, 23: 2310-2317. 10.1200/JCO.2005.00.034. A published erratum appears in J Clin Oncol 2006, 24:531View ArticlePubMedGoogle Scholar
- Finlayson EV, Birkmeyer JD: Operative mortality with elective surgery in older adults. Eff Clin Pract. 2001, 4: 172-177. A published erratum appears in Eff Clin Pract 2001, 4:235PubMedGoogle Scholar
- Ancona E, Rampado S, Cassaro M, Battaglia G, Ruol A, Castoro C, Portale G, Cavallin F, Rugge M: Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008, 15: 3278-3288. 10.1245/s10434-008-0065-1.View ArticlePubMedGoogle Scholar
- Evans JA, Early DS, Chandraskhara V, Chathadi KV, Fanelli RD, Fisher DA, Foley KQ, Hwang JH, Jue TL, Pasha SF, Sharaf R, Shergill AK, Dominitz JA, Cash BD, ASGE Standards of Practice Committee: The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc. 2013, 77: 328-334. 10.1016/j.gie.2012.10.001.View ArticlePubMedGoogle Scholar
- Hashimoto S, Kobayashi M, Takeuchi M, Sato Y, Narisawa R, Aoyagi Y: The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc. 2011, 74: 1389-1393. 10.1016/j.gie.2011.07.070.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.